Cargando…

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications

Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilization. However, considerable variation in their use and prices. Objective: Assess the influence of multiple supply and demand-side ini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godman, Brian, Wettermark, Bjorn, van Woerkom, Menno, Fraeyman, Jessica, Alvarez-Madrazo, Samantha, Berg, Christian, Bishop, Iain, Bucsics, Anna, Campbell, Stephen, Finlayson, Alexander E., Fürst, Jurij, Garuoliene, Kristina, Herholz, Harald, Kalaba, Marija, Laius, Ott, Piessnegger, Jutta, Sermet, Catherine, Schwabe, Ulrich, Vlahović-Palčevski, Vera V., Markovic-Pekovic, Vanda, Vončina, Luka, Malinowska, Kamila, Zara, Corinne, Gustafsson, Lars L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060455/ https://www.ncbi.nlm.nih.gov/pubmed/24987370 http://dx.doi.org/10.3389/fphar.2014.00106

Ejemplares similares

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
por: Godman, Brian, et al.
Publicado: (2014)

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
por: Malmström, Rickard E., et al.
Publicado: (2013)

Personalizing health care: feasibility and future implications
por: Godman, Brian, et al.
Publicado: (2013)

Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications
por: Godman, Brian, et al.
Publicado: (2011)

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
por: Ermisch, Michael, et al.
Publicado: (2016)

Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
por: Godman, Brian, et al.
Publicado: (2010)

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
por: Adamski, Jakub, et al.
Publicado: (2010)

Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications
por: Bojanić, Ljubica, et al.
Publicado: (2018)

Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries
por: Pisana, Alice, et al.
Publicado: (2022)

Initiatives to Reduce Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications
por: Marković-Peković, Vanda, et al.
Publicado: (2017)

Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications
por: Tubic, Biljana, et al.
Publicado: (2021)

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
por: de Bruijn, Winnie, et al.
Publicado: (2016)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
por: Vella Bonanno, Patricia, et al.
Publicado: (2017)

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications
por: Godman, Brian, et al.
Publicado: (2014)

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
por: Ferrario, Alessandra, et al.
Publicado: (2017)

Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future
por: Godman, Brian, et al.
Publicado: (2013)

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
por: Godman, Brian, et al.
Publicado: (2021)

Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”
por: Godman, Brian, et al.
Publicado: (2023)

Pharmacists’ clinical knowledge and practice in the safe use of contraceptives: real knowledge vs. self-perception and the implications
por: Jelić, Ana Golić, et al.
Publicado: (2021)

Discounts and rebates granted to public payers for medicines in European countries
por: Vogler, Sabine, et al.
Publicado: (2012)

Corrigendum: Variations in the Consumption of Antimicrobial Medicines in the European Region, 2014–2018: Findings and Implications From ESAC-Net and WHO Europe
por: Robertson, Jane, et al.
Publicado: (2021)

Variations in the Consumption of Antimicrobial Medicines in the European Region, 2014–2018: Findings and Implications from ESAC-Net and WHO Europe
por: Robertson, Jane, et al.
Publicado: (2021)

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Poluzzi, Elisabetta, et al.
Publicado: (2015)

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
por: Godman, Brian, et al.
Publicado: (2018)

Antimicrobial Prescribing Preparedness of Croatian Medical Students—Did It Change between 2015 and 2019?
por: Palčevski, Dora, et al.
Publicado: (2023)

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Raschi, Emanuel, et al.
Publicado: (2013)

Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up
por: Kalinić, Dragan, et al.
Publicado: (2022)

Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
por: Bochenek, Tomasz, et al.
Publicado: (2018)

Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018
por: Peñalva, Germán, et al.
Publicado: (2019)

Antibiotic Utilization during COVID-19: Are We Over-Prescribing?
por: Bednarčuk, Nataša, et al.
Publicado: (2023)

Time trends in statin utilisation and coronary mortality in Western European countries
por: Vancheri, Federico, et al.
Publicado: (2016)

Different initiatives across Europe to enhance losartan utilization post generics: impact and implications
por: Moon, James C., et al.
Publicado: (2014)

Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System
por: Eriksson, Irene, et al.
Publicado: (2018)

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
por: Milic, Sandra, et al.
Publicado: (2015)

Analysis of the Gut Microbiome and Dietary Habits in Metastatic Melanoma Patients with a Complete and Sustained Response to Immunotherapy
por: Golčić, Marin, et al.
Publicado: (2023)

Eleven-Year Trends in Lipid-Modifying Medicines Utilisation and Expenditure in a Low-Income Country: A Study from the Republic of Srpska, Bosnia and Herzegovina
por: Kalinić, Dragan, et al.
Publicado: (2023)

Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series
por: Markovic, Srdjan, et al.
Publicado: (2021)

Policies for biosimilar uptake in Europe: An overview
por: Moorkens, Evelien, et al.
Publicado: (2017)

The European challenges of funding orphan medicinal products
por: Szegedi, Márta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kr2vv43dgp09f9vva5sdtrcb66